StockData

Mereo BioPharma vs XTL Biopharmaceuticals

MREO and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MREO and XTLB compare

Mereo BioPharma scores higher on the StockData Score (1 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMREOXTLB
Size and price
Market cap$219M–
Share price$0.275$1.62
Change, 1 year−84.6%−56.0%
Change, 5 years−85.6%−86.5%
Beta (5Y)2.291.14
Employees393
StockData Score
Total score1 (better)0
Valuation score00
Growth score00
Performance score00
Health score1 (better)0
Dividend score00
Valuation
P/B9.2×–
FCF yield−10.1%–
Profitability
Return on equity−76.6%–
Financial health
Interest coverage−440.6×−6.3× (better)
Current ratio5.22–
Altman Z-score−4.68–
Piotroski F-score4–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions7.1%0.00%
Held by insiders0.18%0.00%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.